Episode 512: ENZA-P Nature Medicine translational data
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Podcast Index
Browse podcasts by category, open recent episodes, and download audio to listen offline.
The Uromigos
The Uromigos
קבלה מדיה | mp4 #kab_heb
Bnei Baruch Kabbalah Education and Research Institute, Бней Барух – Ассоциация "Каббала Ла-Ам"
RADIO KULTURAEUROPA
RADIO KULTURAEUROPA
Dad’s Bedtime Stories
Stories for Kids
What you talking about Willis?
WYTAW
زاوية المجلة
al majalla / مجلة المجلة
The BelTel
Belfast Telegraph
Tech News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Seattle News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Ö1 Journale
ORF Ö1
Cinema Hot Takes
Author Adidas Wilson
Lanterne Rouge Cycling Podcast
Lanterne Rouge Media, SL
Truth Changes Everything
Dr. Jeff Myers: President of Summit Ministries
Covino & Rich
Fox Sports Radio and iHeartPodcasts
The Dan Patrick Show
iHeartPodcasts and Dan Patrick Podcast Network
Locked On Senators - Daily Podcast On The Ottawa Senators
Ross Levitan, Brandon Piller, Locked On Podcast Network
Pittsburgh Penguins News Today | 2 Min News | The Daily News Now!
The Daily News Now!
TestGuild Automation Podcast
Joe Colantonio
Serial Killer Documentary Show
Sizzle
Siste nytt fra VG
VG
The Baseball Prospectus Podcast Network
Bret Sayre
The Patrick Madrid Show
Relevant Radio
How To Academy Podcast
How To Academy
MovarekhPodcast احمدهاشمی
احمد هاشمی
برامج
مونت كارلو الدولية / MCD
Mystery Story Time
shubham saini
Lydia's Lunch Bunch
Lydia Media
Spike Week
Spike Week
Crush City Territory: A Houston Astros Podcast
Foul Territory Network
The Ben and Ashley I Almost Famous Podcast
iHeartPodcasts
Hintergrund
Deutschlandfunk
Hip-Hop News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Chad Roberts Podcast
Chad Roberts
Sign Of The Times(Late Show)
Wtf-Landia Radio Late Show
All
The Uromigos
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and ...
This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent stud...
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.
This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and inn...
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts di...
This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, c...
Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026
In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of d...
Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.
Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer a...
This session from APCCC 2026 features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in current practices, challenges, and future directions in radi...
This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-dri...
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-ri...
Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment d...
Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.
In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights...
Fill in the form below. Make sure to select both Country and Genres.
Send us a message below. We will get back to you within 24 hours.